Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15048513 | 0.94 | L3MBTL1 (0.53) | TSHRL3MBTL1MCL1FFAR4TP53 | |
| SCHEMBL3731595 | 0.90 | L3MBTL1 (0.67) | TSHRL3MBTL1MCL1TP53ALOX15 | |
| SCHEMBL11355811 | 0.83 | TP53 (0.46) | TSHRL3MBTL1MCL1TP53ALOX15 | |
| SCHEMBL826321 | 0.82 | SMN1; SMN2 (0.65) | TSHRL3MBTL1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL6883728 | 0.81 | L3MBTL1 (0.82) | TSHRL3MBTL1FFAR4PPARGFFAR1 | |
| SCHEMBL11504186 | 0.80 | MCL1 (0.58) | TSHRL3MBTL1MCL1FFAR4FFAR1 | |
| SCHEMBL22434873 | 0.80 | L3MBTL1 (0.59) | TSHRL3MBTL1MCL1FFAR4FFAR1 | |
| SCHEMBL4389091 | 0.80 | BRD4 (0.53) | TP53ALOX15 | |
| SCHEMBL5725093 | 0.79 | FFAR1 (0.42) | TSHRL3MBTL1MCL1TP53ALOX15 | |
| SCHEMBL13008056 | 0.78 | MCL1 (0.47) | TSHRL3MBTL1MCL1FFAR4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2094311-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| CN-1356913-A | vitronectin receptor antagonist drugs | DU PONT PHARM CO (US) | 2002-07-03 | — | — | CN | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| WO-2002004030-A2 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | TSHR 899/4885L3MBTL1 4391/4885MCL1 1210/4885 |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | TSHR 1922/4885L3MBTL1 512/4885MCL1 410/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | TSHR 428/4885L3MBTL1 3077/4885MCL1 691/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | TSHR 410/4885L3MBTL1 2840/4885MCL1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.